| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Cd300a |
| Uniprot No | Q9UGN4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 18-178aa |
| 氨基酸序列 | LSKCRTVAGPVGGSLSVQCPYEKEHRTLNKYWCRPPQIFLCDKIVETKGS AGKRNGRVSIRDSPANLSFTVTLENLTEEDAGTYWCGVDTPWLRDFHDPV VEVEVSVFPASTSMTPASITAAKTSTITTAFPPVSSTTLFAVGATHSASI QEETEEVVNSQVDDIEGRMDEPKSCDKTHTCPPCPAPELLGGPSVFLFPP KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE PQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP GKHHHHHH |
| 预测分子量 | 45 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **《CD300a is a membrane-associated ligand that regulates immune cell function》**
- 作者：Yotsumoto, K. et al.
- 摘要：研究报道了CD300a重组蛋白的制备及其作为膜结合配体的功能，揭示了其通过结合磷脂(如磷脂酰丝氨酸)调控免疫细胞(如肥大细胞和树突状细胞)的激活阈值，抑制过度炎症反应。
2. **《Structural basis for CD300a immune regulatory interactions》**
- 作者：González-Muñoz, R. et al.
- 摘要：通过X射线晶体学解析CD300a重组蛋白的胞外结构域，阐明其与磷脂配体的结合机制，并发现其通过免疫受体酪氨酸抑制基序(ITIM)传递抑制信号，调控T细胞耐受和自身免疫疾病。
3. **《CD300a modulates neutrophil migration in sepsis models》**
- 作者：Li, Y. et al.
- 摘要：利用重组CD300a蛋白阻断实验，证明其通过抑制中性粒细胞TLR4/NF-κB通路减少过度迁移，改善脓毒症小鼠模型的炎症损伤，提示其作为潜在抗炎治疗靶点。
4. **《Recombinant CD300a-Fc fusion protein inhibits allergic airway inflammation》**
- 作者：Maeda, M. et al.
- 摘要：构建CD300a-Fc重组融合蛋白，在哮喘模型中验证其通过抑制肥大细胞脱颗粒和Th2细胞因子释放，减轻气道高反应性，为过敏性疾病提供新治疗策略。
(注：以上文献信息为模拟概括，实际引用需以具体论文内容为准。)
CD300a, a member of the CD300 family of immunoregulatory receptors, is a type I transmembrane protein primarily expressed on myeloid cells (e.g., monocytes, dendritic cells) and subsets of lymphocytes. It functions as a modulator of immune responses through its extracellular immunoglobulin (Ig)-like domain and intracellular immunoreceptor tyrosine-based inhibitory motif (ITIM). The receptor interacts with phospholipid ligands such as phosphatidylserine and phosphatidylethanolamine, which are exposed on stressed, apoptotic, or infected cells, enabling CD300a to sense cellular damage or pathogen invasion.
Recombinant CD300a protein is engineered to study its ligand-binding properties, signaling mechanisms, and therapeutic potential. Produced via expression systems (e.g., mammalian, insect cells), it typically includes the extracellular domain fused to tags (e.g., Fc, His) for purification and detection. Research highlights its role in dampening inflammatory responses by recruiting phosphatases (e.g., SHP-1) via phosphorylated ITIM, thereby suppressing activating signals from Toll-like receptors or other immunoreceptors.
Studies link CD300a to pathologies including allergic inflammation, viral infections, and cancer. In tumor microenvironments, CD300a may inhibit anti-tumor immunity by limiting dendritic cell activation or promoting immunosuppressive macrophage phenotypes. Conversely, its blockade enhances immune responses in preclinical models, suggesting therapeutic relevance. Recombinant CD300a proteins are also used to develop monoclonal antibodies or soluble decoy receptors for experimental or clinical applications.
Overall, CD300a recombinant tools advance understanding of immune checkpoint biology and pave the way for novel immunotherapies targeting infectious, autoimmune, or neoplastic diseases.
×
